Carvedilol Reduces the Inappropriate Increase of Ventilation During Exercise in Heart Failure Patients* Study objective: To evaluate the effects of
|
|
- Abner Stanley McKinney
- 6 years ago
- Views:
Transcription
1 Carvedilol Reduces the Inappropriate Increase of Ventilation During Exercise in Heart Failure Patients* Piergiuseppe Agostoni, MD, PhD, FCCP; Marco Guazzi, MD, PhD; Maurizio Bussotti, MD; Stefano De Vita, MD; and Pietro Palermo, MD; Study objective: To evaluate the effects of -blockers on ventilation in heart failure patients. Indeed, -blockers ameliorate the clinical condition and cardiac function of heart failure patients, but not exercise capacity. Because ventilation is inappropriately elevated in heart failure patients due to overactive reflexes from ergoreceptors and chemoreceptors, we hypothesized that -blockers can elicit their positive clinical effects through a reduction of ventilation. Design: This was a double-blind, randomized, placebo-controlled study. Setting: University hospital heart failure unit. Patients and interventions: While receiving placebo (2 months) and a full dosage of carvedilol (4 months), 15 chronic heart failure patients were evaluated by quality-of-life questionnaire, pulmonary function tests, cardiopulmonary exercise tests with constant workload, and a ramp protocol. Results: Therapy with carvedilol did not affect resting pulmonary function and exercise capacity. However, carvedilol improved the results of the quality-of-life questionnaire, reduced the mean ( SD) slope of the minute ventilation (V E)/carbon dioxide output (V CO2 ) ratio (from to ; p < 0.01) and reduced ventilation at the following times: at peak exercise (from to L/min; p < 0.05); during the intermediate phases of a ramp-protocol exercise; and during the steady-state phase of a constant-workload exercise (from to L/min; p < 0.05, at third min). The end-expiratory pressure for carbon dioxide increased as ventilation decreased. The reduction in the V E/V CO2 ratio was correlated with improvement in quality of life (r 0.603; p < 0.02). Conclusions: Improvement in the clinical conditions of heart failure patients treated with carvedilol is associated with reductions in the inappropriately elevated ventilation levels observed during exercise. (CHEST 2002; 122: ) Key words: carvedilol; exercise; heart failure; oxygen uptake; ventilation Abbreviations: Petco 2 end-expiratory pressure for carbon dioxide; V co 2 carbon dioxide output; V e minute ventilation; V o 2 oxygen uptake Long-term treatment with -blockers ameliorates the clinical condition and cardiac function of patients with heart failure. 1 3 However, this does not translate into an improvement in exercise capacity during both maximal and submaximal effort. 4 6 A lack of appropriate chronotropic response has been suggested as the possible cause of the incapacity of *From the Centro Cardiologico, Monzino, Istituto di Ricovero e Cura a Carattere Scientifico, Istituto di Cardiologia, Università di Milano, Milan, Italy. This research has been supported by a research grant of the Centro Cardiologico Monzino, IRCCS. Manuscript received September 6, 2001; revision accepted May 14, Correspondence to: Piergiuseppe Agostoni, MD, PhD, FCCP, Centro Cardiologico, Monzino, Istituto di Cardiologia, Università di Milano, via Parea 4, Milan, Italy; Piergiuseppe. Agostoni@cardiologicomonzino.it -blockers to improve exercise performance. 7 However, the difference between heart rates at rest and at peak exercise is not affected by -blocker therapy reducing both the resting and peak exercise heart rates. 8 Ventilation for a given work rate is inappropriately increased in heart failure patients, but ventilation at peak exercise is lower as the severity of the disease becomes greater We have suggested previously that the lack of increase in ventilation at peak exercise could be the cause of the absence of improvement in exercise capacity during long-term treatment with -blockers in heart failure patients. 5,8 Recently, Ponikowski et al 12 showed that the inappropriate increase of ventilation for a given work rate in heart failure patients was due to the widespread derangement of cardiovascular reflexes, which are 2062 Clinical Investigations
2 driven through sympathetic pathways. This conclusion proposes a new rationale for the use of -blocker therapy in heart failure patients and suggests why -blocker therapy does not improve exercise capacity and ventilation. Materials and Methods Study Design and Data Acquisition This was a double-blind, randomized, placebo-controlled study. All patients who participated in the study underwent a study run-in period of 2 weeks, during which clinical stability was assessed and patients performed at least two cardiopulmonary exercise tests (ramp protocol) to become familiarized with the exercise procedure. Patients were randomized to two groups (A and B), composed of eight and seven subjects, respectively. The study protocol is summarized in Figure 1. It was 8 months long and contained a carvedilol titration period of 2 months, during which the carvedilol dose was increased by 12.5 mg every 2 weeks under clinical and ECG surveillance. 13 The titration period was guided by an investigator who used labeled carvedilol pills and did not participate in any other part of the investigation. The full carvedilol dosage was defined as the highest carvedilol dose that could be tolerated by the patients during the carvedilol titration period. The full carvedilol dosage was administered for 4 months, while the placebo treatment lasted for 2 months. In group A, placebo titration preceded carvedilol titration and treatment. In group B, placebo titration followed carvedilol titration. During the study, patients were clinically evaluated every 15 days, or more often if required or desired by the patients. At the end of each treatment period, patients underwent the following evaluations. (1) Quality of life was evaluated utilizing the Minnesota quality-of-life questionnaire, which is a standard and selfadministered questionnaire. It consists of 21 brief questions, each of which is answered on a scale of 0 to 5, with 0 indicating no effect of heart failure and 5 indicating a very large effect. 14 (2) Standard pulmonary function tests and a lung diffusion evaluation for carbon monoxide (2200; SensorMedics; Yorba Linda, CA) were administered. (3) Two cardiopulmonary exercise tests were given. One was a constant-workload exercise test of 6 min duration with a workload equal to the 60% of the maximal workload measured in the second familiarization exercise test performed in the run-in period. The other was a maximal exercise test with a personalized ramp protocol that was aimed at achieving peak exercise in 10 min, as evaluated in the study run-in period. Thereafter, the workload of both the constant and ramp protocol was kept the same in each patient. Both of the exercise tests were performed on the cycle ergometer, with breath-by-breath respiratory gas and volume measurements (V Max; SensorMedics). The anaerobic threshold was calculated using the V-slope analysis and the respiratory compensation point as the point where the slope of the minute ventilation (V e)/ carbon dioxide output (V co 2 ) relationship started to increase. 15 For evaluation, the data were averaged over the 30 s during which the examined event occurred. Patient Population Patients were enrolled consecutively in the study and were heart failure patients who had been referred to the Heart Failure Unit of the Centro Cardiologico Monzino, Department of Cardiology, University of Milan, who met the study inclusion/ exclusion criteria. Patients were classified as being in New York Heart Association functional classes II (six patients) and III (nine patients). The etiology of heart failure was idiopathic dilated cardiomyopathy in all cases. All patients were receiving optimized and personally tailored anti-heart failure treatment, which was kept constant throughout the study. Treatment included therapy with diuretics in all patients, antialdosterone therapy in 7 patients, digoxin in 7 patients, angiotensin-converting enzyme inhibitors in 13 patients, angiotensin II type 1 blockers in 3 patients, and amiodarone in 4 patients. Inclusion criteria were as Figure 1. Design of the study protocol. CHEST / 122 / 6/ DECEMBER,
3 Table 1 Resting Pulmonary Function and Diffusion of Both Groups Combined* Variables Placebo Carvedilol FEV 1, L/s Vital capacity, L MVV, L/min Dlco, ml/min/mm Hg *Values given as mean SD. MVV maximal voluntary ventilation; Dlco diffusing capacity of the lung for carbon monoxide. follows: stable clinical condition with heart failure known for at least 6 months; the absence of previous or current -blocker treatment; an echocardiographic ejection fraction of 40%; and normal findings from coronary angiography. Exclusion criteria included a history of and/or clinical evidence of myocardial infarction, uncontrolled diabetes, COPD, peripheral vascular disease, primary pulmonary hypertension, effort-induced cardiac ischemia, angina, or arrhythmia. We enrolled 15 patients (13 men and 2 women) with a mean ( SD) age of 56 8 years. The mean weight, height, and body surface area were kg, cm, and m 2, respectively. The mean left ventricle ejection fraction was 32 10%, with a mean left ventricle end-diastolic diameter of 68 9 mm. Our Human Research Committee approved the study. The protocol was explained to the patients in detail, and afterward they provided written consent to be enrolled in the research trial. Data Analysis The data are reported as the mean SD. Differences within groups were evaluated by two-way repeated measures analysis of variance (see Tables 2 4). Differences between the two groups combined were analyzed by paired t test. The relationship between differences in the Minnesota Living with Heart Failure Quality-of-Life Questionnaire vs V e/v co 2 slope with treatment was analyzed by linear regression analysis. A p value 0.05 was considered to be statistically significant. Results All patients completed the trial. No difference was observed between the two groups regarding patients characteristics, treatment, or heart failure severity. The mean carvedilol-tolerated dosage was mg, with no differences between the two groups. The Minnesota Living with Heart Failure Qualityof-Life Questionnaire scored a mean of with placebo and with carvedilol (p 0.05). Resting pulmonary function is reported in Table 1. Constant-workload exercise was performed at W, which is above the anaerobic threshold (which was measured at and W, respectively, with placebo and carvedilol) but below the respiratory compensation point (86 24 and W [p 0.05], respectively, with placebo and carvedilol). The difference in oxygen uptake (V o 2 ) between the sixth and third minutes was ml/min ([p 0.05]) [group A, ml/min; group B, ml/min) and ml min (group A, ml/min; group B, ml/min), respectively, with placebo and carvedilol. Values for ventilation, endexpiratory pressure for carbon dioxide (Petco 2 ) and V co 2 at the third and sixth minute of constantworkload exercise are reported in Table 2. With carvedilol therapy, ventilation was lower and Petco 2 was higher, both at the third and sixth minute of constant-workload exercise, while V co 2 was not significantly changed by treatment. Carvedilol therapy did not affect exercise capacity. The peak V o 2 and maximal work rate were unaffected by treatment (Tables 3 and 4). At peak exercise, carvedilol reduced ventilation, tidal volume, and V co 2 (Table 3 and 4). Carvedilol also reduced the V e/v co 2 ratio slope from to (p 0.01). Figure 2 reports the value of the V e/v co 2 ratio slope in all subjects. The horizontal line indicates 2 SDs above the mean value for healthy subjects. 15 The reduction of the V e/v co 2 ratio slope by carvedilol therapy was greater in patients with high V e/v co 2 ratio values. Finally, Table 2 Ventilation, PETCO 2, and V CO2 at the Third and Sixth Minutes of Constant-Workload Exercise Values While on Placebo and Carvedilol* Ventilation, L/min Petco 2,mmHg V co 2, ml/min Groups Third minute Sixth minute Third minute Sixth minute Third minute Sixth minute Group A Placebo , , Carvedilol , , Group B Placebo , , Carvedilol , , Both groups combined Placebo , , Carvedilol , , *Values given as mean SD Clinical Investigations
4 Table 3 Cardiopulmonary Measurements at Peak Exercise (Ramp Protocol)* Group A Group B Variables Placebo Carvedilol Placebo Carvedilol V o 2 ml/min 1, , , , ml/kg/min V co 2, ml/min 1, , , , Maximal work rate W % predicted V e, L/min Vt, ml RR, beats/min Petco 2,mmHg *Values given as mean SD. Vt tidal volume; RR respiratory rate. the V e/v co 2 ratio slope changes were correlated with the Minnesota Living with Heart Failure Quality-of-Life Questionnaire score improvement (r 0.603; p 0.02) [Fig 3]. The major regulatory mechanisms of ventilation are V co 2 and the CO 2 set point. The CO 2 set point can be noninvasively estimated by the Petco 2 during exercise before the metabolic compensation point is reached (Table 5). As shown in Figure 4, carvedilol therapy increased the CO 2 set point, particularly in patients with the poorest exercise capacity. Discussion This study shows, as do several previous reports, 1 7,13 that clinical condition, but not exercise capacity, improves in patients with heart failure that has been treated with carvedilol. This well-known discrepancy is relevant because exercise capacity correlates with the clinical condition of and prognosis for heart failure patients, and carvedilol has been shown to improve both. 1 4,13 We advance the hypothesis that the sensation of well-being that has been observed in many patients who have been treated with -blockers is related to a reduction of the inappropriate increase of ventilation, which is frequently observed in heart failure patients. Measurements of ventilatory parameters during constant-workload exercise and measurements of V e/v co 2 ratio slope, respiratory compensation point, ventilatory data at the maximal Petco 2 and at peak exercise on the ramp exercise test were made for this purpose. During constant-workload exercise, carvedilol significantly reduced ventilation and increased Petco 2 to a normal value despite minor changes in V co 2. This means that the inappropriate increase of ventilation is reduced by carvedilol therapy. This might be due to a reduction in the increased excitatory inputs on ventilation from overactive ergoreflexes and chemoreflexes. 12,20 22 The positive effects of carvedilol on ventilation are not paralleled by effects on V o 2. Indeed, the peak V o 2 was unaffected by carvedilol administration, and the difference in V o 2 between the sixth and the third minutes of a constant-workload exercise, which is an index of exercise performance, 23 increased with carvedilol therapy, showing, if anything, a deterioration of exercise performance. This could be due to a lack of proper cardiac output increase or inappropriate O 2 availability/utilization at the muscular level during exercise. Accordingly, the respiratory compensation point, which takes place when isocapnic buffering for metabolic acidosis ends, 15 occurs at a lower workload with carvedilol treatment. We defined the maximal Petco 2 as the highest Table 4 Cardiopulmonary Measurements at Peak Exercise in Both Groups Combined (Ramp Protocol)* Variables Placebo Carvedilol V o 2 ml/min 1, , ml/kg/min V co 2, ml/min 1, , Maximal work rate W % predicted V e, L/min Vt, ml RR, beats/min Petco 2,mmHg *Values given as mean SD. See Table 3 for abbreviations not used in the text. CHEST / 122 / 6/ DECEMBER,
5 Table 5 Ventilation, V CO2, and Work Rate at Maximal PETCO 2 (Ramp Protocol)* Groups Placebo Carvedilol Figure 2. The ramp exercise protocol. V e/v co 2 slope in placebo and carvedilol is shown in all subjects (group A, F; and group B, E). Triangles indicate the mean SD of both groups combined. The horizontal dotted line indicates 2 SDs above the mean of healthy subjects. * p value of Petco 2 recorded during a ramp exercise test. This measurement was observed between the anaerobic threshold and the respiratory compensation point when Petco 2 remains constant. 15 The observation that with carvedilol the recorded maximal Petco 2 was higher and ventilation was lower with an unchanged V co 2 (Table 5) strongly favors a reduction of V co 2 -independent regulation of ventilation. It is of note that carvedilol-induced changes in maximal Petco 2 are greater in those patients with the poorest exercise performance (ie, those patients who are more likely have inappropriately increased ventilation) [Fig 4]. The data at peak exercise show a lower ventilation Group A Maximal Petco 2,mmHg Ventilation, L/min V co 2 at maximal Petco 2, ml/min Group B Maximal Petco 2,mmHg Ventilation, L/min V co 2 at maximal Petco 2, ml/min Both groups combined Maximal Petco 2,mmHg Ventilation, L/min V co 2 at maximal Petco 2, ml/min *Values given as mean SD. with carvedilol due to the reduction of tidal volume. Therefore, at first glance it is possible to suggest that carvedilol reduces ventilation at peak exercise because of a negative mechanical action on the lungs. However, under such circumstances one would expect the following: (1) a reduced peak V o 2 and work rate, whereas both remained unchanged; or (2) ventilation at peak exercise to be near the maximal level of voluntary ventilation, whereas it was at 50% (Tables 1 and 3). 24 Two mechanisms might be responsible for the reduction in peak exercise ventilation. First, it is possible that at peak exercise, as happens during exercise (see the data for constant workload and maximal Petco 2 exercise), a reduction in reflex-increased ventilation takes place. Second, the lower V co 2 values observed at peak exercise during carvedilol treatment imply a reduced metabolic production of CO 2. Figure 3. Correlation between differences ( ) in the Minnesota Living with Heart Failure Quality-of-Life Questionnaire (QLT) and the V e/v co 2 ratio slope between placebo and carvedilol treatment (r 0.603; p 0.02). See the legend of Figure 2 for an explanation of the symbols used. Figure 4. Differences in the maximal Petco 2 ( Petco 2 ) between placebo and carvedilol treatment vs peak V o 2 with placebo. Carvedilol increased the maximal Petco 2, particularly in patients with the poorest exercise performance. See the text for details. See the legend of Figure 2 for an explanation of the symbols used Clinical Investigations
6 The slope of the V e/v co 2 ratio is probably the best indicator of an inappropriate increase of ventilation. 25,26 Its reduction shows that carvedilol reduces the inappropriate increase of ventilation in heart failure patients, which agrees with all the observations reported earlier. Carvedilol therapy reduces the V e/v co 2 ratio slope, and this reduction correlates with the changes in the Minnesota Living with Heart Failure Quality-of-Life Questionnaire results. This suggests that the sensation of well-being that is reported during carvedilol treatment is related to a reduction of ventilation that takes place not only at peak exercise but also at a workload comparable with normal life activities. Moreover, the V e/v co 2 ratio slope is a prognostic indicator that is even stronger than peak V o 2. 27,28 In conclusion, the improvement in the clinical conditions of patients treated with carvedilol seems to be related to a reduction in the inappropriate increase of ventilation characteristics of heart failure patients. References 1 Krum H, Sackner-Bernstein JD, Goldsmith RL, et al. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation 1995; 92: Colucci WS, Packer M, Bristow MR, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 1996; 94: Packer M, Colucci WS, Sackner-Bernstein JD, et al. Doubleblind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: the PRECISE Trial; Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation 1996; 94: Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996; 94: Guazzi M, Agostoni P, Matturri M, et al. Pulmonary function, cardiac function, and exercise capacity in a follow-up of patients with congestive heart failure treated with carvedilol. Am Heart J 1999; 138: Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997; 349: Metra M, Nodari S, D Aloia A, et al. Effects of neurohormonal antagonism on symptoms and quality-of-life in heart failure. Eur Heart J 1998; 19:B25 B35 8 Guazzi M, Agostoni PG. Monitoring gas exchange during a constant work rate exercise in patients with left ventricular dysfunction treated with carvedilol. Am J Cardiol 2000; 85: Sullivan MJ, Higginbotham MB, Cobb FR. Increased exercise ventilation in patients with chronic heart failure: intact ventilatory control despite hemodynamic and pulmonary abnormalities. Circulation 1988; 77: Metra M, Dei Cas L, Panina G, et al. Exercise hyperventilation chronic congestive heart failure, and its relation to functional capacity and hemodynamics. Am J Cardiol 1992; 70: Wasserman K, Zhang YY, Gitt A, et al. Lung function and exercise gas exchange in chronic heart failure. Circulation 1997; 96: Ponikowski P, Francis DP, Piepoli MF, et al. Enhanced ventilatory response to exercise in patients with chronic heart failure and preserved exercise tolerance: marker of abnormal cardiorespiratory reflex control and predictor of poor prognosis. Circulation 2001; 103: Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure: MOCHA Investigators. Circulation 1996; 94: Rector TS, Kubo SH, Cohn JN. Validity of the Minnesota Living with Heart Failure questionnaire as a measure of therapeutic response to enalapril or placebo. Am J Cardiol 1993; 71: Wasserman K, Hansen JE, Sue DY, et al. Principles of exercise testing and interpretation. 3rd ed. Baltimore, MD: Lippincott Williams & Wilkins 1999; Chua TP, Ponikowski P, Harrington D, et al. Clinical correlates and prognostic significance of the ventilatory response to exercise in chronic heart failure. J Am Coll Cardiol 1997; 29: Mancini DM, Eisen H, Kussmaul W, et al. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 1991; 83: Weber KT, Janicki JS. Cardiopulmonary exercise testing for evaluation of chronic cardiac failure. Am J Cardiol 1985; 55:22A 31A 19 Szlachcic J, Massie BM, Kramer BL, et al. Correlates and prognostic implication of exercise capacity in chronic congestive heart failure. Am J Cardiol 1985; 55: Chua TP, Clark AL, Amadi AA, et al. Relation between chemosensitivity and the ventilatory response to exercise in chronic heart failure. J Am Coll Cardiol 1996; 27: Ponikowski P, Chua TP, Piepoli M, et al. Augmented peripheral chemosensitivity as a potential input to baroreflex impairment and autonomic imbalance in chronic heart failure. Circulation 1997; 96: Piepoli M, Clark AL, Volterrani M, et al. Contribution of muscle afferents to the hemodynamic, autonomic, and ventilatory responses to exercise in patients with chronic heart failure: effects of physical training. Circulation 1996; 93: Zhang YY, Wasserman K, Sietsema KE, et al. O 2 uptake kinetics in response to exercise: a measure of tissue anaerobiosis in heart failure. Chest 1993; 103: Agostoni PG, Butler J. Cardiac evaluation. In: Murray J, Nadel A. eds. Textbook of respiratory medicine. 2nd ed. Philadelphia, PA: WB Saunders, 1994; Clark AL, Volterrani M, Swan JW, et al. The increased ventilatory response to exercise in chronic heart failure: relation to pulmonary pathology. Heart 1997; 77: Reindl I, Wernecke KD, Opitz C, et al. Impaired ventilatory efficiency in chronic heart failure: possible role of pulmonary vasoconstriction. Am Heart J 1998; 136: Kleber FX, Vietzke G, Wernecke KD, et al. Impairment of ventilatory efficiency in heart failure: prognostic impact. Circulation 2000; 101: Robbins M, Francis G, Pashkow FJ, et al. Ventilatory and heart rate responses to exercise: better predictors of heart failure mortality than peak oxygen consumption. Circulation 1999; 100: CHEST / 122 / 6/ DECEMBER,
In patients with left ventricular failure during exercise,
Exercise-Induced Pulmonary Edema in Heart Failure Piergiuseppe Agostoni, MD, PhD; Gaia Cattadori, MD; Michele Bianchi, MD; Karlman Wasserman, MD, PhD Background In heart failure (HF) patients, exercise
More informationExercise Anaerobic Threshold and Ventilatory Efficiency Identify Heart Failure Patients for High Risk of Early Death
Exercise Anaerobic Threshold and Ventilatory Efficiency Identify Heart Failure Patients for High Risk of Early Death Anselm K. Gitt, MD; Karlman Wasserman, MD, PhD; Caroline Kilkowski, MD; Thomas Kleemann,
More informationARTICLE IN PRESS. Determining the Best Ventilatory Efficiency Measure to Predict Mortality in Patients with Heart Failure
ARTICLE IN PRESS Determining the Best Ventilatory Efficiency Measure to Predict Mortality in Patients with Heart Failure Robert L. Bard, MA, a Brenda W. Gillespie, PhD, b Nicholas S. Clarke, a Timothy
More informationCPX and Prognosis in Cardiovascular Disease
CPX and Prognosis in Cardiovascular Disease Anselm K. Gitt, Piergiuseppe Agostoni Herzzentrum Ludwigshafen, Germany Instituto di Cardiologia Università di Milano, Milan, Italy Cardiopulmonary exercise
More informationS everal lines of evidence suggest that gas diffusion across
453 CARDIOVASCULAR MEDICINE Does lung diffusion impairment affect exercise capacity in patients with heart failure? P G Agostoni M Bussotti P Palermo M Guazzi... See end of article for authors affiliations...
More informationEnd-tidal pressure of CO 2 and exercise performance in healthy subjects
DOI 10.1007/s00421-008-0773-z ORIGINAL ARTICLE End-tidal pressure of CO 2 and exercise performance in healthy subjects Maurizio Bussotti Æ Damiano Magrì Æ Emanuele Previtali Æ Stefania Farina Æ Anna Torri
More informationExercise Stress Testing: Cardiovascular or Respiratory Limitation?
Exercise Stress Testing: Cardiovascular or Respiratory Limitation? Marshall B. Dunning III, Ph.D., M.S. Professor of Medicine & Physiology Medical College of Wisconsin What is exercise? Physical activity
More informationJohn G Lainchbury, A Mark Richards
538 * Heart failure EXERCISE TESTING IN THE ASSESSMENT OF CHRONIC CONGESTIVE HEART FAILURE John G Lainchbury, A Mark Richards Heart 22;88:538 543 See end of article for authors affiliations c PRACTICAL
More informationComparison of the prognostic value of cardiopulmonary exercise testing between male and female patients with heart failure
International Journal of Cardiology 113 (2006) 395 400 www.elsevier.com/locate/ijcard Comparison of the prognostic value of cardiopulmonary exercise testing between male and female patients with heart
More informationEffects of Exercise Training on Abnormal Ventilatory Responses to Exercise in Patients with Chronic Heart Failure
EXERCISE AND ABNORMAL VENTILATION IN CHF CHF SEPTEMBER/OCTOBER 2000 243 Effects of Exercise Training on Abnormal Ventilatory Responses to Exercise in Patients with Chronic Heart Failure Patients with chronic
More informationKey words: exercise capacity; heart failure; hemodynamics; inspiratory capacity; lung function; peak oxygen uptake
Resting Lung Function and Hemodynamic Parameters as Predictors of Exercise Capacity in Patients With Chronic Heart Failure* Serafim Nanas, MD; John Nanas, MD, PhD; Ourania Papazachou, MD; Christos Kassiotis,
More informationCardiopulmonary exercise testing with gas-exchange measurement
Enhanced Ventilatory Response to Exercise in Patients With Chronic Heart Failure and Preserved Exercise Tolerance Marker of Abnormal Cardiorespiratory Reflex Control and Predictor of Poor Prognosis Piotr
More informationtodays practice of cardiopulmonary medicine
todays practice of cardiopulmonary medicine Concepts and Applications of Cardiopulmonary Exercise Testing* Karl T. Weber, M.D.; Joseph S. Janicki, Ph.D.; Patricia A. McElroy, M.D.; and Hanumanth K. Reddy,
More informationDyspnea is a common exercise-induced
MK pg 214 Mædica - a Journal of Clinical Medicine STATE-OF-THE-ART Cardiopulmonary exercise testing in differential diagnosis of dyspnea Nora TOMA, MD; Gabriela BICESCU, MD, PhD; Raluca ENACHE, MD; Ruxandra
More informationPrognostic usefulness of the functional aerobic reserve in patients with heart failure
Prognostic usefulness of the functional aerobic reserve in patients with heart failure Paul Chase, MEd, a Ross Arena, PhD, PT, b,c,d Marco Guazzi, MD, PhD, e Jonathan Myers, PhD, f Mary Ann Peberdy, MD,
More informationFOLLOW-UP MEDICAL CARE OF SERVICE MEMBERS AND VETERANS CARDIOPULMONARY EXERCISE TESTING
Cardiopulmonary Exercise Testing Chapter 13 FOLLOW-UP MEDICAL CARE OF SERVICE MEMBERS AND VETERANS CARDIOPULMONARY EXERCISE TESTING WILLIAM ESCHENBACHER, MD* INTRODUCTION AEROBIC METABOLISM ANAEROBIC METABOLISM
More informationOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOO
OOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOO Subject Index ACE inhibitors, see Angiotensin-converting enzyme inhibitors Aging
More informationCardiopulmonary Exercise Test (CPET) Evaluation Report
Cardiopulmonary Exercise Test (CPET) Evaluation Report Name: Sally Alpha Date: Test 1 November 29, 2015 Test 2 November 30, 2015 Findings: Sally Alpha demonstrates poor functional capacity and early onset
More informationCardiopulmonary exercise testing for prognosis in chronic heart failure: continuous and independent prognostic value from VE/VCO 2 slope and peak VO 2
European Heart Journal (2000) 21, 154 161 Article No. euhj.1999.1863, available online at http://www.idealibrary.com on Cardiopulmonary exercise testing for prognosis in chronic heart failure: continuous
More informationPhysiological Insights of Exercise Hyperventilation in Pulmonary Hypertension
Physiological Insights of Exercise Hyperventilation in Pulmonary Hypertension Stefania Farina MD, Noemi Bruno MD, Cecilia Agalbato MD, Mauro Contini MD, Roberto Cassandro MD, Davide Elia MD, Sergio Harari
More informationby Excerpta Medica, Inc. All rights reserved /04/$ see front matter
Differential Contribution of Dead Space Ventilation and Low Arterial pco 2 to Exercise Hyperpnea in Patients With Chronic Heart Failure Secondary to Ischemic or Idiopathic Dilated Cardiomyopathy Roland
More informationPrimary pulmonary hypertension (PPH) is a progressive
Exercise Pathophysiology in Patients With Primary Pulmonary Hypertension Xing-Guo Sun, MD; James E. Hansen, MD; Ronald J. Oudiz, MD; Karlman Wasserman, MD, PhD Background Patients with primary pulmonary
More informationEffects of Gender on Peak Oxygen Consumption and the Timing of Cardiac Transplantation
Journal of the American College of Cardiology Vol. 47, No. 11, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.11.089
More informationRelationship of resting haemoglobin concentration to peak oxygen uptake in heart failure patients
Relationship of resting haemoglobin concentration to peak oxygen uptake in heart failure patients Piergiuseppe Agostoni, Elisabetta Salvioni, Chiara Debenedetti, Carlo Vignati, Gaia Cattadori, Mauro Contini,
More informationL esercizio fisico e le patologie cardiorespiratorie: dalla valutazione funzionale alla prescrizione. M. Guazzi
La Riabilitazione Interdisciplinare L esercizio fisico e le patologie cardiorespiratorie: dalla valutazione funzionale alla prescrizione M. Guazzi Università di Milano Dipartimento Cardiologia Universitaria
More informationMeet the expert ME6 Heart failure-copd overlap and cardiovascular responses to exercise: a cardiologist s perspective
ERS Annual Congress Milan 09 13 September 2017 Meet the expert ME6 Heart failure-copd overlap and cardiovascular responses to exercise: a cardiologist s perspective Monday, 11 September 2017 13:00-14:00
More information11/12/2018. Prof. Steven S. Saliterman. Options. Prof. Paul Iaizzo s Physiology Lab, PHSL 3701
Department of Biomedical Engineering, University of Minnesota http://saliterman.umn.edu/ Prof. Paul Iaizzo s Physiology Lab, PHSL 3701 Options University of Minnesota Bricker, E. Compass, 5 Types of Cardiac
More informationAbnormal Heart Rate Recovery Immediately After Cardiopulmonary Exercise Testing in Heart Failure Patients
Abnormal Heart Rate Recovery Immediately After Cardiopulmonary Exercise Testing in Heart Failure Patients Tuba BILSEL, 1 MD, Sait TERZI, 1 MD, Tamer AKBULUT, 1 MD, Nurten SAYAR, 1 MD, Gultekin HOBIKOGLU,
More informationTesting Clinical Implications
Cardiopulmonary Exercise Testing Clinical Implications Dr Sahajal Dhooria Outline Basic concepts Case studies Recent advances in clinical applications of CPET Basic Concepts Exercise Any physical activity
More informationLong-Term Outcome and Tolerability of Carvedilol Therapy in Japanese Patients With Chronic Heart Failure
Long-Term Outcome and Tolerability of Carvedilol Therapy in Japanese Patients With Chronic Heart Failure Naomi Naoki Yoko Yoshie Hiroshi KAWASHIRO, MD MATSUDA, MD ENDO, MD UCHIDA, MD KASANUKI, MD, FJCC
More informationI Can t Breathe! Physiology and Evaluation of the Dyspneic Patient. Christopher Parker, MD Pulmonology, Norman Regional Health Systems
I Can t Breathe! Physiology and Evaluation of the Dyspneic Patient Christopher Parker, MD Pulmonology, Norman Regional Health Systems Photo by James Heilman, MD / CC BY-SA 3.0 Disclosures No Financial
More informationChronic heart failure (CHF) is a major cause of morbidity
Systolic Blood Pressure Response to Exercise as a Predictor of Mortality in Patients With Chronic Heart Failure Yasuhiro Nishiyama, 1 MD, Hirohiko Morita, 1 MD, Haruhito Harada, 1 MD, Atsushi Katoh, 1
More informationPrimary pulmonary hypertension (PPH) is a rapidly progressive
Effects of Iloprost Inhalation on Exercise Capacity and Ventilatory Efficiency in Patients With Primary Pulmonary Hypertension Roland Wensel, MD; Christian F. Opitz, MD; Ralf Ewert, MD; Leonhard Bruch,
More informationChapter 21: Clinical Exercise Testing Procedures
Publisher link: thepoint http://thepoint.lww.com/book/show/2930 Chapter 21: Clinical Exercise Testing Procedures American College of Sports Medicine. (2010). ACSM's resource manual for guidelines for exercise
More informationAerobic Training Decreases B-Type Natriuretic Peptide Expression and Adrenergic Activation in Patients With Heart Failure
Journal of the American College of Cardiology Vol. 47, No. 9, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.12.050
More informationPatients with right-to-left intracardiac shunts regulate arterial
Gas Exchange Detection of Exercise-Induced Right-to-Left Shunt in Patients With Primary Pulmonary Hypertension Xing-Guo Sun, MD; James E. Hansen, MD; Ronald J. Oudiz, MD; Karlman Wasserman, MD, PhD Background
More informationAtrial fibrillation (AF) occurs in both patients with overt
Prognostic Value of Cardiopulmonary Exercise Testing in Cardiac Patients With Atrial Fibrillation Summary Hidekazu Tsuneoka, 1,2 MD, Akira Koike, 1 MD, Osamu Nagayama, 1 BS, Koji Sakurada, 1 MS, Jo Kato,
More informationCardiopulmonary Exercise Test The Most Powerful Tool to Detect Hidden Pathophysiology
REVIEW ARTICLE Cardiopulmonary Exercise Test The Most Powerful Tool to Detect Hidden Pathophysiology Hitoshi Adachi, 1 MD Summary The cardiopulmonary exercise test (CPX) is an essential examination for
More informationComparison of Exercise Performance in Patients With Chronic Severe Heart Failure Versus Left Ventricular Assist Devices
Comparison of Exercise Performance in Patients With Chronic Severe Heart Failure Versus Left Ventricular Assist Devices Donna Mancini, MD; Rochelle Goldsmith, PhD; Howard Levin, MD; Ainat Beniaminovitz,
More informationCardiopulmonary Exercise Testing in the Clinical and Prognostic Assessment of Diastolic Heart Failure
Journal of the American College of Cardiology Vol. 46, No. 10, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.07.051
More informationA Simple New Visualization of Exercise Data Discloses Pathophysiology and Severity of Heart Failure
A Simple New Visualization of Exercise Data Discloses Pathophysiology and Severity of Heart Failure James E. Hansen, MD; Xing-Guo Sun, MD; William W. Stringer, MD Background -The complexity of cardiopulmonary
More informationClinical exercise testing
Basic principles of clinical exercise testing Clinical exercise testing This article is adapted from the on Basic principles of clinical exercise testing organised in Rome, March 2 4, 2006. Original slides,
More informationAtriobiventricular Pacing Improves Exercise Capacity in Patients With Heart Failure and Intraventricular Conduction Delay
Journal of the American College of Cardiology Vol. 41, No. 4, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Science Inc. doi:10.1016/s0735-1097(02)02849-8
More informationEligibility for cardiac transplantation relies heavily on the
Peak Oxygen Consumption as a Predictor of Death in Patients With Heart Failure Receiving -Blockers James O. O Neill, MB, MRCPI; James B. Young, MD; Claire E. Pothier, MA, MPH; Michael S. Lauer, MD Background
More informationVentilatory Anaerobic Threshold and Improves
324 Exercise Training in Patients With Chronic Heart Failure Delays Ventilatory Anaerobic Threshold and Improves Submaximal Exercise Performance Martin J. Sullivan, MD, Michael B. Higginbotham, MB, and
More informationEndurance ability characteristics of professional sportsmen
Proceeding 6th INSHS International Christmas Sport Scientific Conference, 11-14 December 2011. International Network of Sport and Health Science. Szombathely, Hungary Endurance ability characteristics
More informationJames E. Hansen, MD, FCCP; Gaye Ulubay, MD; Bing Fai Chow, MD; Xing-Guo Sun, MD; and Karlman Wasserman, PhD, MD, FCCP
CHEST Original Research EXERCISE TESTING Mixed-Expired and End-Tidal CO 2 Distinguish Between Ventilation and Perfusion Defects During Exercise Testing in Patients With Lung and Heart Diseases* James E.
More information16. Exercise Energetics
16. Exercise The performance of muscular exercise not only throws a strain on the musculoskeletal system itself but it also tests the reserves of virtually every system in the body. Exercising muscles
More informationCardiopulmonary Exercise Testing: its principles, interpretation & application. DM Seminar Harshith
Cardiopulmonary Exercise Testing: its principles, interpretation & application DM Seminar Harshith Outline Physiology of exercise Introduction Equipment and working Principles Interpretation and variables
More informationAerobic Conditioning in Mild Asthma Decreases the Hyperpnea of Exercise and Improves Exercise and Ventilatory Capacity*
preliminary report Aerobic Conditioning in Mild Asthma Decreases the Hyperpnea of Exercise and Improves Exercise and Ventilatory Capacity* Teal S. Hallstrand, MD; Peter W. Bates, MD, FCCP; and Robert B.
More informationKey words: exercise therapy; exercise tolerance; lung diseases; obstructive; oxygen consumption; walking
Exercise Outcomes After Pulmonary Rehabilitation Depend on the Initial Mechanism of Exercise Limitation Among Non-Oxygen-Dependent COPD Patients* John F. Plankeel, MD; Barbara McMullen, RRT; and Neil R.
More informationOptimal Adrenergic Blockades in Heart Failure. Jae-Joong Kim MD, PhD Asan Medical Center, University of Ulsan, Seoul, Korea
Optimal Adrenergic Blockades in Heart Failure Jae-Joong Kim MD, PhD Asan Medical Center, University of Ulsan, Seoul, Korea Contents Harmful effects of adrenergic system in heart failure Clinical studies
More informationT he prevalence of heart failure is increasing throughout the
239 CARDIOVASCULAR MEDICINE Ventilatory variables are strong prognostic markers in elderly patients with heart failure M Mejhert, E Linder-Klingsell, M Edner, T Kahan, H Persson... See end of article for
More information(CPX) testing. Although this is usually attributed to a submaximal effort, a portion of this
KENJALE, AARTI, M.S., Predicting Survival Probability for Major Congestive Heart Failure Events in Patients Attaining a Low Peak Respiratory Exchange Ratio during Cardiopulmonary Exercise Testing. (2008)
More informationClinical Study Oxygen Kinetics and Heart Rate Response during Early Recovery from Exercise in Patients with Heart Failure
Cardiology Research and Practice Volume 1, Article ID 5157, 7 pages doi:1.1155/1/5157 Clinical Study Oxygen Kinetics and Heart Rate Response during Early Recovery from Exercise in Patients with Heart Failure
More informationExercise-Induced Rise in Arterial Potassium in Patients With Chronic Heart Failure*
Exercise-Induced Rise in Arterial Potassium in Patients With Chronic Heart Failure* Relation to Excessive Exercise Ventilation Yasuhiko Tanabe, MD; Masahiro Ito, MD; Yukio Hosaka, MD; Eiichi Ito, MD; Kaoru
More informationBasics of Cardiopulmonary Exercise Test Interpretation. Robert Kempainen, MD Hennepin County Medical Center
Basics of Cardiopulmonary Exercise Test Interpretation Robert Kempainen, MD Hennepin County Medical Center None Conflicts of Interest Objectives Explain what normally limits exercise Summarize basic protocol
More informationMaximal cardiopulmonary testing has increased
Utility of the Breathing Reserve Index at the Anaerobic Threshold in Determining Ventilatory-Limited Exercise in Adult Cystic Fibrosis Patients* William P. Sexauer, MD, FCCP; Ho-Kan Cheng, MD; and Stanley
More informationCardiac Output MCQ. Professor of Cardiovascular Physiology. Cairo University 2007
Cardiac Output MCQ Abdel Moniem Ibrahim Ahmed, MD Professor of Cardiovascular Physiology Cairo University 2007 90- Guided by Ohm's law when : a- Cardiac output = 5.6 L/min. b- Systolic and diastolic BP
More informationVE/VCO 2 slope and its prognostic value in patients with chronic heart failure
EXPERIMENTAL AND THERAPEUTIC MEDICINE 9: 1407-1412, 2015 VE/VCO 2 slope and its prognostic value in patients with chronic heart failure YUQIN SHEN 1*, XIAOYU ZHANG 2*, WENLIN MA 1, HAOMING SONG 1, ZHU
More informationJournal of the American College of Cardiology Vol. 37, No. 7, by the American College of Cardiology ISSN /01/$20.
Journal of the American College of Cardiology Vol. 37, No. 7, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(01)01268-2 Exercise
More informationCatecholamines contribute to exertional dyspnoea and to the ventilatory response to exercise in normal humans
European Heart Journal (1997) 18, 1829-1833 Catecholamines contribute to exertional dyspnoea and to the ventilatory response to exercise in normal humans A.L. Clarkf, S. Galloway*, N. MacFarlane*f, E.
More informationSimple prediction formula for peak oxygen consumption in patients with chronic heart failure
Available online at www.sciencedirect.com Journal of Exercise Science & Fitness 10 (2012) 23e27 Original article Simple prediction formula for peak oxygen consumption in patients with chronic heart failure
More informationCirculating Plasma Surfactant Protein Type B as Biological Marker of Alveolar-Capillary Barrier Damage in Chronic Heart Failure
Circulating Plasma Surfactant Protein Type B as Biological Marker of Alveolar-Capillary Barrier Damage in Chronic Heart Failure Damiano Magrì, MD; Maura Brioschi, PhD; Cristina Banfi, PhD; Jean Paul Schmid,
More informationHemodynamic Effects of Vasodilators and Long-Term Response in Heart Failure
JACC Vol. 3, No.6 1521 REPORTS ON THERAPY Hemodynamic Effects of Vasodilators and Long-Term Response in Heart Failure JOSEPH A. FRANCIOSA, MD, FACC, W. BRUCE DUNKMAN, MD, FACC,* CHERYL L. LEDDY, MD* Philadelphia,
More informationExercise hyperventilation in chronic heart failure is not caused by systemic lactic acidosis
The European Journal of Heart Failure 7 (05) 1105 1111 www.elsevier.com/locate/heafai Exercise hyperventilation in chronic heart failure is not caused by systemic lactic acidosis Abstract Roland Wensel
More informationRespiratory Pathophysiology Cases Linda Costanzo Ph.D.
Respiratory Pathophysiology Cases Linda Costanzo Ph.D. I. Case of Pulmonary Fibrosis Susan was diagnosed 3 years ago with diffuse interstitial pulmonary fibrosis. She tries to continue normal activities,
More informationExercise stroke volume and heart rate response differ in right and left heart failure
European Journal of Heart Failure (2010) 12, 716 720 doi:10.1093/eurjhf/hfq062 Exercise stroke volume and heart rate response differ in right and left heart failure Herman Groepenhoff 1 *, Nico Westerhof
More informationJournal of the American College of Cardiology Vol. 37, No. 2, by the American College of Cardiology ISSN /01/$20.
Journal of the American College of Cardiology Vol. 37, No. 2, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)01158-X Dilated
More informationBenefits of Combined Aerobic/Resistance/Inspiratory Muscle Training in Patients with Chronic Heart Failure. The Ideal Exercise Program for CHF?
Benefits of Combined Aerobic/Resistance/Inspiratory Muscle Training in Patients with Chronic Heart Failure. The Ideal Exercise Program for CHF? I D. Laoutaris, S Adamopoulos, A Manginas, D B. Panagiotakos,
More informationSpironolactone improves lung diffusion in chronic heart failure
European Heart Journal (2005) 26, 159 164 doi:10.1093/eurheartj/ehi023 Clinical research Spironolactone improves lung diffusion in chronic heart failure Piergiuseppe Agostoni*, Alessandra Magini, Daniele
More informationRita Calé, Miguel Mendes, António Ferreira, João Brito, Pedro Sousa, Pedro Carmo, Francisco Costa, Pedro Adragão, João Calqueiro, José Aniceto Silva.
Peak Circulatory Power : a new parameter of cardiopulmonary exercise testing to predict arrhythmic events in patients with implantable cardioverter defibrillator for primary prevention Rita Calé, Miguel
More informationEffect of Short-term Maximal Exercise on BNP Plasma Levels in. Healthy Individuals
1 Effect of Short-term Maximal Exercise on BNP Plasma Levels in Healthy Individuals Jan Krupicka, MD, Tomas Janota, MD, Zdislava Kasalova, MD, Jaromir Hradec, MD 3rd Department of Internal Medicine, 1st
More informationTreating the patient with acute heart failure. What do we really know? Principles of acute heart failure treatment
ESC 2012 27Aug - 3Sep, 2012, Munich, Germany Treating the patient with acute heart failure. What do we really know? Principles of acute heart failure treatment Marco Metra, MD, FESC Cardiology University
More informationDobutamine-induced increase in heart rate is blunted by ivabradine treatment in patients with acutely decompensated heart failure
Dobutamine-induced increase in heart rate is blunted by ivabradine treatment in patients with acutely decompensated heart failure Yuksel Cavusoglu, KU Mert, A Nadir, F Mutlu, E Gencer, T Ulus, A Birdane
More informationCardiopulmonary Exercise Testing Cases
Canadian Respiratory Conference - 217 Cardiopulmonary Exercise Testing Cases Darcy D Marciniuk, MD FRCPC FCCP Associate Vice-President Research, University of Saskatchewan Professor, Respirology, Critical
More informationCLINICAL INVESTIGATION OF ANTI-ANGINAL MEDICINAL PRODUCTS IN STABLE ANGINA PECTORIS
CLINICAL INVESTIGATION OF ANTI-ANGINAL MEDICINAL PRODUCTS IN STABLE ANGINA PECTORIS Guideline Title Clinical Investigation of Anti-Anginal Medicinal Products in Stable Angina Pectoris Legislative basis
More informationTo Correlate Ejection Fraction with 6 Minute Walked Distance and Quality of Life in Patients with Left Ventricular Heart Failure
To Correlate Ejection Fraction with 6 Minute Walked Distance and Quality of Life in Patients with Left Ventricular Heart Failure Pramila S Kudtarkar*, Mariya P Jiandani*, Ashish Nabar** Abstract Purpose
More informationResting Heart Rate Does Not Reflect the Degree of Beta-Blockade in Subjects with Heart Failure on Chronic Beta-Blocker Therapy
RESEARCH Resting Heart Rate Does Not Reflect the Degree of Beta-Blockade in Subjects with Heart Failure on Chronic Beta-Blocker Therapy Andrea Mignatti, Daniel B. Sims, Paolo C. Colombo, Luis I. Garcia,
More informationExercise Testing and Training in Heart Failure Patients Robert S. McKelvie, MD, PhD, FRCPC, Hamilton Health Sciences - General Division
Exercise Testing and Training in Heart Failure Patients Robert S. McKelvie, MD, PhD, FRCPC, Hamilton Health Sciences - General Division Studies have demonstrated that there is no relationship between left
More informationJournal of the American College of Cardiology Vol. 44, No. 12, by the American College of Cardiology Foundation ISSN /04/$30.
Journal of the American College of Cardiology Vol. 44, No. 12, 2004 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2004.09.041
More informationExercise tests are commonly used in clinical practice for
Exercise in Cardiovascular Disease Cardiopulmonary Exercise Testing in the Clinical Evaluation of Patients With Heart and Lung Disease Ross Arena, PhD, PT, FAHA; Kathy E. Sietsema, MD Exercise tests are
More informationDefinition of Congestive Heart Failure
Heart Failure Definition of Congestive Heart Failure A clinical syndrome of signs & symptoms resulting from the heart s inability to supply adequate tissue perfusion. CHF Epidemiology Affects 4.7 million
More informationThe benefit of treatment with -blockers in heart failure is
Heart Rate and Cardiac Rhythm Relationships With Bisoprolol Benefit in Chronic Heart Failure in CIBIS II Trial Philippe Lechat, MD, PhD; Jean-Sébastien Hulot, MD; Sylvie Escolano, MD, PhD; Alain Mallet,
More informationGoing to high altitude with heart disease. Prof. Dr. med. Stefano Rimoldi High Altitude Medicine Inselspital Bern
Going to high altitude with heart disease Prof. Dr. med. Stefano Rimoldi High Altitude Medicine Inselspital Bern stefano.rimoldi@insel.ch There are very few studies on patients with heart disease going
More informationThe Management of Heart Failure after Biventricular Pacing
The Management of Heart Failure after Biventricular Pacing Juan M. Aranda, Jr., MD University of Florida College of Medicine, Division of Cardiovascular Medicine, Gainesville, Florida Approximately 271,000
More informationGuide to the interpretation of Cardiopulmonary Exercise Testing
Guide to the interpretation of Cardiopulmonary Exercise Testing Dr. Ines Frederix December 2014 Copyright: Ines Frederix 1 Ergospirometry: parameter description... 5 1.1 Cardiovascular parameters... 5
More informationCardiovascular Responses to Exercise
CARDIOVASCULAR PHYSIOLOGY 69 Case 13 Cardiovascular Responses to Exercise Cassandra Farias is a 34-year-old dietician at an academic medical center. She believes in the importance of a healthy lifestyle
More informationHFPEF Echo with Strain vs. MRI T1 Mapping
HFPEF Echo with Strain vs. MRI T1 Mapping Erik Schelbert, MD MS Director, Cardiovascular Magnetic Resonance Assistant Professor of Medicine Heart & Vascular Institute University of Pittsburgh Disclosures
More informationFocus on the role of Catheter Ablation: Simple cases Intermediate level Difficult cases (and patients) Impossible (almost )
22nd SHA Scientific Session 21 24 February 2011, Riyadh, KSA Management of Ventricular Arrhythmias: an Overview Corrado Carbucicchio Ventricular Intensive Care Unit Cardiac Arrhythmias Research Centre
More informationTrials Enrolled subjects Findings Fox et al. 2014, SIGNIFY 1
Appendix 5 (as supplied by the authors): Published trials on the effect of ivabradine on outcomes including mortality in patients with different cardiovascular diseases Trials Enrolled subjects Findings
More informationStress echo workshop STRESSORS
Stress echo workshop STRESSORS Adham Ahmed, MD Lecturer of Cardiology, Ain Shams Indications of Stress Echo CAD Diagnosis Prognosticat ion 1 Physiologic Basis 1930s: Tennant and Wiggers Relationship between
More informationSteven S. Saliterman, MD, FACP
Ashley Wagner, Sochi 2014 www.gotceleb.com Steven S. Saliterman, MD, FACP Adjunct Professor Department of Biomedical Engineering, University of Minnesota http://saliterman.umn.edu/ Aerobic (Oxidative Phosphorylation)
More informationObjective: Prepare NBRC candidate for CRT and WRT Content Outline
STRESS TEST AND HEMODYNAMICS Lois Rowland, MS, RRT-NPS, RPFT, FAARC Objective: Prepare NBRC candidate for CRT and WRT Content Outline Perform, evaluate patient response to, interpret results from: Stress
More informationAnnual Congress of the European Society of Cardiology Munich, August
Annual Congress of the European Society of Cardiology Munich, August 26 2012 Gas exchange measurements during exercise show early pulmonary arterial hypertension in scleroderma patients Daniel Dumitrescu,
More informationTitle : Adaptation to exercise
Title : Adaptation to exercise Teacher: Magdalena Gibas MD PhD Coll. Anatomicum, 6 Święcicki Street, Dept. of Physiology I. Exercise physiology 1. The acute and chronic responses to exercise depend upon
More informationCHRONIC HEART FAILURE : WHAT ELSE COULD WE OFFER TO OUR PATIENTS? Cardiac Rehabilitation Society of Thailand
CHRONIC HEART FAILURE : WHAT ELSE COULD WE OFFER TO OUR PATIENTS? Cardiac Rehabilitation Society of Thailand ENHANCED EXTERNAL COUNTER PULSATION Piyanuj Ruckpanich, MD. Cardiac Rehabilitation Center Perfect
More informationHeart Rate Response to Graded Exercise Correlates with Aerobic and Ventilatory Capacity in Patients with Heart Failure
Clin. Cardiol. 28, 25 29 (2005) Heart Rate Response to Graded Exercise Correlates with Aerobic and Ventilatory Capacity in Patients with Heart Failure ALESSANDRO VALLEBONA, M.D., GUIDO GIGLI, M.D., SANDRO
More informationChronic heart failure (HF) is among the most frequent. Considerations on Safety and Treatment of Patients with Chronic Heart Failure at High Altitude
HIGH ALTITUDE MEDICINE & BIOLOGY Volume 14, Number 2, 2013 ª Mary Ann Liebert, Inc. DOI: 10.1089/ham.2012.1117 Considerations on Safety and Treatment of Patients with Chronic Heart Failure at High Altitude
More informationCardiopulmonary Exercise Testing: Relevant But Underused
Global reprints distributed only by Postgraduate Medicine USA. No part of Postgraduate Medicine may be reproduced or transmitted in any form without written permission from the publisher. All permission
More information